Patents Examined by Sean R Donohue
-
Patent number: 11918662Abstract: Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.Type: GrantFiled: June 10, 2021Date of Patent: March 5, 2024Assignee: CHDI Foundation, Inc.Inventors: Longbin Liu, Matthew Lee, Celia Dominguez, Peter David Johnson, Catherine Jane Greenaway, Kanika Khurana, Matthew Robert Mills, Filippo Rota
-
Patent number: 11890356Abstract: Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.Type: GrantFiled: November 16, 2021Date of Patent: February 6, 2024Assignee: The General Hospital CorporationInventors: Jacob Hooker, Changning Wang, Martin Georg Strebl-Bantillo, Johanna Kaarina Rokka
-
Patent number: 11851446Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.Type: GrantFiled: June 21, 2021Date of Patent: December 26, 2023Assignee: CHDI Foundation, Inc.Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Alex Kiselyov, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Daniel Clark-Frew
-
Patent number: 11845763Abstract: Complex compounds of transition metals according to formula (1) wherein the M(CO)3+ tricarbonyl-metal core forms a complex with the cyclopentadienyl anion linked to heterocyclic moieties of the benzothiazole, benzimidazole and benzoxazole families. The compounds exhibit high blood-brain barrier permeability and can be used in the diagnosis and/or treatment of diseases of the Central Nervous System.Type: GrantFiled: March 22, 2019Date of Patent: December 19, 2023Assignee: NATIONAL CENTRE FOR SCIENTIFIC RESEARCH “DEMOKRITOS”Inventors: Maria Pelecanou Zampara, Marina Sagnou, Minas Papadopoulos, Ioannis Pirmettis, Barbara Mavroidi, Antonio Shegani
-
Patent number: 11844846Abstract: This disclosure relates to styrylbenzothiazole derivatives for use as in vivo imaging agents for the diagnosis of Parkinson's disease (PD) or other degenerative disorders or conditions of the central nervous system. Early diagnosis is particularly advantageous as neuroprotective treatment can be applied to healthy neural cells to delay or even prevent the onset of debilitating clinical symptoms.Type: GrantFiled: May 16, 2019Date of Patent: December 19, 2023Assignee: EMORY UNIVERSITYInventor: Keqiang Ye
-
Patent number: 11839663Abstract: The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.Type: GrantFiled: September 29, 2020Date of Patent: December 12, 2023Assignee: Janssen Pharmaceutica NVInventors: Gang Chen, Chaofeng Huang, Jimmy T. Liang
-
Patent number: 11833228Abstract: Beta-hydroxybutyric acid-based radiopharmaceuticals, pharmaceutical compositions comprising same, methods for preparing same, and methods of using same for diagnostic imaging and non-imaging tracer studies are provided.Type: GrantFiled: August 13, 2020Date of Patent: December 5, 2023Assignee: The Governors Of The University Of AlbertaInventors: Stephanie Mattingly, Frank Wuest, Ralf Schirrmacher, Melinda Wuest, Eugene Fine
-
Patent number: 11833229Abstract: The invention relates to a marking precursor incorporating a chelator or fluorination group for radiolabelling with 44Sc, 47Sc, 55Co, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 89Zr, 86Y, 90Y, 90Nb, 99mTc, 111In, 135Sm, 140Pr, 159Gd, 149Tb, 160Tb, 161Tb, 165Er, 166Dy, 166Ho, 175Yb, 177Lu, 186Re, 188Re, 213Bi and 225Ac or with 18F, 131I or 211At, and one or two biological targeting vectors which are coupled to the chelator or fluorinating group via one or more squaric acid groups.Type: GrantFiled: May 16, 2022Date of Patent: December 5, 2023Assignee: SCV Spezial-Chemikalien-Vertriebs GmbHInventors: Frank Rösch, Lukas Greifenstein, Nils Engelbogen, Ralf Bergmann
-
Patent number: 11826435Abstract: The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of 18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of ?-glucocerebrosidase activity.Type: GrantFiled: October 19, 2018Date of Patent: November 28, 2023Assignee: UNIVERSITY OF SASKATCHEWANInventors: Christopher Phenix, Daniel Tesolin, Morshed Chowdhury, Shusheng Wang
-
Patent number: 11801315Abstract: A radioligand for labeling myelin includes a fluorescent trans-stilbene derivative.Type: GrantFiled: September 8, 2020Date of Patent: October 31, 2023Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Yanming Wang, Chunying Wu
-
Patent number: 11779665Abstract: Provided herein are methods of fluorinating organic compounds. The electrochemical fluorination and radiofluorination of organic molecules using the cation pool technique is described, where the 18F and/or 19F-fluorine ions are added after the process of electrochemical oxidation, i.e., after formation of a carbocationic organic compound (i.e., a compound having a carbon atom with a positive charge).Type: GrantFiled: February 4, 2019Date of Patent: October 10, 2023Assignee: The Regents of the University of CaliforniaInventors: Saman Sadeghi, Mehrdad Balandeh
-
Patent number: 11752223Abstract: A method for producing an 225Ac solution includes a step (I) of irradiating a 226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least 225Ac, a step (II) of dissolving the 226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating 226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than 225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with 225Ac, and a targeting agent.Type: GrantFiled: July 20, 2022Date of Patent: September 12, 2023Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGYInventors: Yoshio Honda, Taku Ito, Jun Ichinose, Hiroaki Ichikawa, Tomoyuki Imai, Kotaro Nagatsu, Hisashi Suzuki
-
Patent number: 11696960Abstract: Methods of detecting an aldehyde-containing compound in a subject or in a sample from a subject are described herein, comprising administering an aldehyde-binding compound of Formula I to the subject, or combining such a compound with the sample; and detecting the product of the compound of Formula I and the aldehyde-containing compound. Detection of the product may involve imaging, such as MRI, CEST-MRI or positron emission tomography (PET) imaging; or may involve fluorescence or an electrochemical detection method. Biologically relevant aldehydes detected according to the described method can be used to monitor conditions such as brain injury, neurodegenerative disorders such as Alzheimer's disease, diabetes, heart disease, and cancer.Type: GrantFiled: February 5, 2018Date of Patent: July 11, 2023Assignee: UNIVERSITY OF OTTAWAInventors: Adam Shuhendler, Mojmir Suchy, Trina Dang
-
Patent number: 11684683Abstract: The invention provides a method for producing a solution containing 211At? (astatide ion) at a high radiochemical purity by using 211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from 211At. The invention also provides a solution containing 211At? (astatide ion) at a radiochemical purity of not less than 30%.Type: GrantFiled: December 28, 2018Date of Patent: June 27, 2023Assignee: OSAKA UNIVERSITYInventors: Yoshifumi Shirakami, Tadashi Watabe, Kazuko Kaneda, Eku Shimosegawa, Atsushi Shinohara, Jun Hatazawa
-
Patent number: 11667628Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: GrantFiled: September 16, 2021Date of Patent: June 6, 2023Assignee: NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGYInventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Patent number: 11666672Abstract: Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.Type: GrantFiled: November 21, 2019Date of Patent: June 6, 2023Assignee: CITY OF HOPEInventors: Susanta Kumar Hui, Paul J. Yazaki, Srideshikan Sargur Madabushi
-
Patent number: 11660357Abstract: Provided herein is a one-step method for chelating actinium-225 to a construct comprising a chelator linked to a bio-molecule, such as, an antibody or monoclonal antibody, via a bifunctional ligand in, for example, a 3-arm configuration. Also provided are methods for increasing the radiochemical yield of an actinium-225-chelant-biomolecule complex and for producing a high specific activity actinium-225 complex. The chelation is performed at a physiological temperature, about 37° C. Also provided are high specific activity actinium-225 complexes, that is, actinium-225 chelated to the chelator-biomolecule construct and pharmaceutical compositions thereof. Further provided are methods of treating a neoplastic disease or disorder with the actinium-225 complexes.Type: GrantFiled: May 18, 2015Date of Patent: May 30, 2023Inventors: David A. Scheinberg, Peter M. Smith-Jones, Michael R. McDevitt, William F. Maguire
-
Patent number: 11633505Abstract: [Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.Type: GrantFiled: December 9, 2013Date of Patent: April 25, 2023Assignees: National University Corporation Kumamoto University, University of Occupational and Enviromental Health, Japan, SBI Pharmaceuticals Co., Ltd.Inventors: Tetsuya Yoneda, Shigeru Nishizawa, Junkoh Yamamoto, Tohru Tanaka, Hidenori Itoh
-
Patent number: 11628229Abstract: A method for preparing 18F radiolabeled biomolecules and agents for 18F-PET imaging is disclosed herein. A perfluoroaryl-conjugated target tracer is synthesized and purified with temperature and solvent conditions that are mild for the tracer molecule. The purified perfluoroaryl-conjugated target tracer is then labeled with 18F using 18F salts within a short reaction time, and with temperature and solvent conditions that are mild for the tracer molecule. The method provides a quick and convenient process that maintains the biological activities of the target molecules. The radio-labeled biomolecules may be used as contrast agents for Positron Emission Tomography (PET).Type: GrantFiled: March 13, 2018Date of Patent: April 18, 2023Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Mark D. Pagel, Iman Daryaei, Abigail Shepard
-
Patent number: 11583596Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.Type: GrantFiled: September 26, 2018Date of Patent: February 21, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNIONInventors: Olivier Meilhac, Emmanuelle Jestin, Florian Guibbal, Sébastien Benard